Table 2.
Steady-state activation and inactivation for INa in heterologously expressed NaCh isoforms and in dog ventricular cardiomyocytes
| Conditions |
SSI Parameters |
SSA Parameters
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| V1/2A, mV | kA, mV | n | V1/2G, mV | kG, mV | n | |||||||
| Heterologously expressed Nav1.2, INaT | ||||||||||||
| nsOligo, 5 days | −70.0±2.6 | −7.7±0.9 | 7 | −21.4±1.5 | 5.1±0.8 | 5 | ||||||
| asOligo, 5 days | −68.9±2.1 | −8.0±0.9 | 7 | −24.1±1.1 | 4.5±0.3 | 5 | ||||||
| Heterologously expressed Nav1.5, INaT | ||||||||||||
| nsOligo, 5 days | −81.4±1.4 | −5.8±0.4 | 9 | −39.7±1.2 | 5.1±0.5 | 7 | ||||||
| asOligo, 5 days | −82.9±0.8 | −5.9±0.3 | 8 | −41.7±1.2 | 5.1±0.3 | 9 | ||||||
| Dog ventricular cardiomyocytes, INaT | ||||||||||||
| Freshly isolated | −80.6±0.7 | −5.7±0.3 | 8 | −38.8±1.5 | 5.1±0.3 | 9 | ||||||
| 5 Days in culture | −81.7±0.9 | −6.2±0.4 | 7 | −36.3±1.5 | 6.3±0.2 | 9 | ||||||
| nsOligo, 5 days | −82.9±0.9 | −6.2±0.2 | 11 | −38.3±1.2 | 5.9±0.2 | 13 | ||||||
| asOligo, 5 days | −82.8±1.2 | −6.9±0.6 | 7 | −37.9±1.1 | 6.3±0.3 | 11 | ||||||
| Dog ventricular cardiomyocytes, INaL | ||||||||||||
| Freshly isolated | −80.0363±0.9 | −6.3±0.5 | 19 | −39.4±0.6 | 7.1±0.1 | 6 | ||||||
| 5 Days in culture | −81.2822± | −5.9±0.6 | 8 | −39.5±0.7 | 7.3±0.5 | 6 | ||||||
| nsOligo, 5 days | −82.0061±1.2 | −5.0±0.8 | 8 | −36.8±1.2 | 6.3±0.3 | 11 | ||||||
| asOligo, 5 days | −80.3534± | −5.1±0.7 | 8 | −37.5±0.7 | 6.4±0.9 | 9 | ||||||
Data are means ± SE; n is cell number. Steady-state inactivation (SSI) and activation (SSA) parameters were obtained from INa data fit to Eqs. 2 and 3 (materials and methods), respectively. We did not find statistically significant differences between parameters within the experimental groups as evaluated by ANOVA followed by Bonferroni's post hoc test. nsOligo, nonsense oligonucleotide; asOligo, antisense oligonucleotide; V1/2A and kA, midpoint and slope of Boltzmann function A curve; V1/2G and kG, midpoint and slope of conductance curve.